Clinical study of Xinkeshu capsule combined with low-dose ticagrelor in the treatment of unstable angina pectoris

Wang Fei; Xu Qin; Wang Wenzhi

doi:10.3760/j.issn.1673-4777.2025.07.021

Abstract：Objective To investigate the efficacy and safety of Xinkeshu capsule combined with low-dose ticagrelor in the treatment of unstable angina pectoris(UAP).Methods A total of 136 UAP patients who were treated in Characteristic Medical Center of Rocket Army from March 2021 to January 2024 were selected.According to the random number table method,they were divided into the control group and the observation group,with 68 cases in each group.The control group was treated with aspirin enteric-coated tablets and low-dose ticagrelor tablets.The observation group was treated with Xinkeshu capsule on the basis of the control group.Both groups were treated for 6 months.The clinical efficacy,traditional Chinese medicine syndrome score,serum levels of interleukin-6(IL-6),C-reactive protein(CRP),malondialdehyde,and glutathione peroxidase(GSH-Px)before and after treatment were compared between the two groups.Bleeding events,cardiovascular events and adverse drug reactions were compared between the two groups.Results The total effective rate of the observation group was significantly higher than that of the control group[95.6％(65/68)vs 85.3％(58/68)](P=0.041).After 6 months of treatment,the scores of chest pain,chest tightness and palpitation in the two groups were lower than those before treatment,and the scores of traditional Chinese medicine syndromes in the observation group were lower than those in the control group(all P＜0.05).After 6 months of treatment,the serum levels of IL-6,CRP and malondialdehyde in the two groups were lower than those before treatment,and the serum level of GSH-Px was higher than that before treatment(all P＜0.05).The serum levels of IL-6,CRP and malondialdehyde in the observation group were lower than those in the control group,and the serum level of GSH-Px was higher than that in the control group(all P＜0.05).There were no moderate bleeding,severe bleeding and cardiovascular events in the two groups.There was no significant difference in the incidence of mild bleeding and adverse reactions between the two groups(both P＞0.05).Conclusion Xinkeshu capsule combined with low-dose ticagrelor has a good clinical effect in the treatment of UAP,which can effectively improve the inflammatory response and oxidative stress response in patients with good safety.